Physician profile
Varkey Mathew
NPI 1245211481
$6,152.62
in general payments reported to CMS, 2019-2025
31 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $751 · 2021: $743 · 2022: $768 · 2023: $813 · 2024: $1,095 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $642.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $639.30 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $528.50 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $506.64 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $440.53 | 2019-2025 | |
| Esperion Therapeutics, INC. | $414.82 | 2020-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $374.40 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Kiniksa Pharmaceuticals, LTD. | $296.65 | 2021-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.73 | 2020-2025 | Jardiance |
| Venclose INC. | $255.42 | 2020 | |
| Aop Health US, LLC | $243.23 | 2025 | Rapiblyk |
| Astrazeneca Pharmaceuticals LP | $218.81 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $191.59 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $181.57 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $150.87 | 2024 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $134.28 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $102.78 | 2020-2021 | |
| Boston Scientific Corporation | $86.45 | 2022-2024 | Varithena Administration Pack |
| Amarin Pharma, INC. | $76.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $52.30 | 2019-2024 | |
| Lundbeck LLC | $46.35 | 2019-2020 | |
| Biocompatibles, INC. | $41.37 | 2019 | |
| Hikma Pharmaceuticals USA | $39.16 | 2019-2020 | |
| Medtronic Vascular, INC. | $38.56 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $32.50 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.11 | 2021-2023 | Lifevest |
| Medtronic, INC. | $28.19 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.47 | 2019 | |
| Abbott Laboratories | $18.99 | 2019 | |
| Ge Healthcare | $18.27 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $14.04 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varkey Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.